Donepezil improves cognitive function and reduces decline in activities of daily living in people with severe Alzheimer's disease.

摘要

At six months, donepezil improved cognitive function compared with placebo in people with severe Alzheimer's disease (least squares mean change from baseline in SIB score: +2.6 with donepezil v -1.9 with placebo; mean difference: 4.5, 95% CI 1.1 to 7.9; p = 0.01; last observation carried forward intention to treat analysis). Donepezil also reduced the decline in activities of daily living compared with placebo at six months (least squares mean change from baseline in ACDS-ADL-severe score: -1.5 with donepezil v -2.9 with placebo; mean difference: 1.4, 95% CI 0.1 to 2.7; p = 0.03). Donepezil and placebo were associated with similar rates of serious adverse events (donepezil v placebo: 24% v 26%). However, more people discontinued owing to adverse events with donepezil than with placebo (donepezil v placebo: 16% v 7%; significance not reported).